Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab plus Chemotherapy in Advanced Gastric/GEJ Cancer
NCT04859582Phase 3Withdrawn
- Sponsor
- Merck & Co.
- Start
- Nov 2018
- Primary completion
- Nov 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of pembrolizumab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Merck & Co.. Planned start Nov 2018; status: withdrawn.
02
Drugs
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT04859582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04859582.